PharmaTher Holdings (QTCQB: PHRRF; CSE: PHRM) has announced that the FDA has approved its ketamine product, KETARx, for use in surgical pain management.
According to PharmaTher, the approval positions the company to contribute to the psychedelic pharmaceutical revolution by leveraging its commercial and clinical initiatives with ketamine towards mental health, neurological, and pain disorders.
In a statement, Fabio Chianelli, founder, chairman, and CEO of PharmaTher, commented, “Today marks a new chapter for PharmaTher. With FDA approval for ketamine now in hand, we are closer to realizing our goal of becoming a global leader in ketamine-based pharmaceuticals. This historic FDA approval for PharmaTher is a testament to years of dedicated development, signaling a new era of growth. We remain steadfast in our mission to harness the pharmaceutical potential of ketamine for a range of mental health, neurological, and pain disorders.”
